Evaluation of Serum Preptin Levels in Patients With Polycystic Ovary Syndrome

ConditionsPolycystic Ovary Syndrome (PCOS)Insulin Resistance

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18-45

SponsorGÜLDEN ANATACA

About this trial

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age and is strongly associated with insulin resistance and metabolic dysfunction. Preptin is a pancreatic peptide co-secreted with insulin and has been implicated in glucose metabolism and insulin resistance. However, limited data exist regarding serum preptin levels in patients with PCOS.

The aim of this study is to evaluate serum preptin levels in women diagnosed with PCOS and to investigate the relationship between preptin levels and insulin resistance parameters.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Female participants aged 18-45 years

Diagnosis of PCOS according to Rotterdam criteria

BMI <30 kg/m²

No PCOS treatment during the previous 6 months

Disqualifiers

Age <18 years or >45 years

Pregnancy or breastfeeding

PCOS treatment within the previous 6 months

Active infection

Trial population

This single-center prospective comparative cross-sectional study will include reproductive-aged women between 18 and 45 years of age who present to the Internal Medicine outpatient clinic with complaints of hirsutism, menstrual irregularity, and hyperandrogenism between June 15, 2026 and September 15, 2026. Participants diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria will constitute the PCOS group. The control group will consist of women with similar clinical complaints who do not meet the Rotterdam diagnostic criteria for PCOS. Only non-obese women with a body mass index (BMI) below 30 kg/m² will be included. Participants with pregnancy, breastfeeding, active infection, chronic systemic disease, rheumatologic or inflammatory disease, diabetes mellitus, hypertension, chronic renal failure, or those receiving treatment for PCOS within the last 6 months will be excluded. All participants will provide written informed consent before enrollment.

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

60 Participants

are grouped into 2 trial groups

Group A: PCOS Group

Group B: Control Group

Trial outcomes

Primary outcomes

Serum Preptin Concentration

Serum preptin concentration measured by enzyme-linked immunosorbent assay (ELISA) and expressed in pg/mL.

Time frame

Baseline

Secondary outcomes

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score. HOMA-IR is a continuous index of insulin resistance calculated from fasting plasma glucose and fasting insulin concentrations. Higher values indicate greater insulin resistance. There is no fixed minimum or maximum score.

Time frame

Baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

GÜLDEN ANATACA

Lead sponsor

Istanbul Saglik Bilimleri University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: